MicuRx Pharmaceuticals, Inc.
  • About MicuRx
    • Our company
    • Our Team
    • Vision & mission
    • History
    • Contact Us
  • Scientific research
    • Antibiotic Resistance
    • Kidney Disease
    • MicuRx R&D
    • Publications
  • Pipeline
  • Newsroom
    • Corporate news
  • Careers
  • Contact Us
  • 中
  • In vivo pharmacodynamic study of contezolid acefosamil, a prodrug of contezolid for oral and intravenous administration

    Time:2023-07-25  /  View:556 times
    Prev: A Novel Leucyl-tRNA Synthetase Inhibitor, MRX-6038, Expresses Anti-Mycobacterium abscessus Activity In Vitro and In Vivo
    Next: A phase I study of the safety, tolerability, and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects
    Back

    Copyright © 2025 All Rights Reserved MicuRx

    Medical Representative Recordation Platform 沪ICP备12020812号

    MicuRx Pharmaceuticals, Inc.